NCT02448784View on ClinicalTrials.gov

Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).

CompletedOBSERVATIONAL

Enrollment

591

Participants

Timeline

Start Date

April 20, 2015

Primary Completion Date

March 30, 2017

Study Completion Date

March 30, 2017

Conditions

Dementia With Lewy Body Disease

Interventions

DRUG

Donepezil Hydrochloride

Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant.

Trial Locations (1)

Unknown

Tokyo

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY

NCT02448784 - Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB). | Biotech Hunter | Biotech Hunter